Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Survival Rates of Patients with Gastric Cancer According to Age and Sex: A Large-Scale Study Using Data from 14,739 Patients: Yonghoon Choi, Nayoung Kim, Ji Hyun Kim, Hyeong Ho Jo, Hyeon Jeong Oh, Hye Seung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, So Hyun Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim; Cancer Res Treat. 2026;58(1):252-263. Published online April 16, 2025; DOI: https://doi.org/10.4143/crt.2025.149

Abstract PDF Supplementary Material PubReader ePub

Purpose
The male predominance in the incidence of gastric cancer (GC) is established; however, sex differences in the prognosis of GC remain controversial. As such, this study analyzed the prognosis of patients with GC based on age and sex.
Materials and Methods
Data from 14,739 patients diagnosed with GC at Seoul National University Bundang Hospital between 2003 and 2023 were analyzed. Baseline characteristics, histological types of GC, overall and GC-specific survival rates (age and stage stratification), and associated risk factors were analyzed.
Results
Females were significantly younger (p < 0.001) and exhibited more gastric body cancers (p < 0.001) and tumors with diffuse-type or poorly differentiated histology (p < 0.001) than males. Females exhibited an advantage over males in terms of overall survival (p=0.004), but not in GC-specific survival. However, age stratification revealed significant sex differences, that females < 50 years of age exhibited survival disadvantages (p < 0.001); however, this trend was reversed with age, and females > 60 years exhibited survival advantages (p < 0.001) for both overall and GC-specific survival. This may be explained by the lower ratio of diffuse-type GC as females age. Furthermore, in the analysis according to stage, females with stage IV disease exhibited significant survival disadvantages, with significantly younger age and a higher proportion of diffuse-type GC which exhibits aggressive features, resulting in poorer survival than in males.
Conclusion
Age and stage stratification revealed significant differences in survival between the sexes, which can be helpful for public health strategies.

Citations

Citations to this article as recorded by

Validation of Textbook Outcome in Gastric Surgery (TOGS) for Primary Gastric Cancer in an Eastern High-Volume Center
Ludovico Carbone, Yo-Seok Cho, Min Kyu Kang, Kyoyoung Park, Jane Chungyoon Kim, Sa-Hong Kim, Jeesun Kim, Nina Rebecca Kalaw, Yoonjin Kwak, Hye Seung Lee, Seong-Ho Kong, Do Joong Park, Daniele Marrelli, Han-Kwang Yang, Franco Roviello, Hyuk-Joon Lee
Annals of Surgical Oncology.2026; 33(8): 7283. CrossRef
Age-related prognostic trends in surgically resected female lymph node-metastatic gastric cancer: insights from SEER
Bozhi Hu, Yinli Zhang, Yingjiang Ye, Zhidong Gao, Chao Wang
International Journal of Clinical Oncology.2026; 31(7): 1307. CrossRef
Sex and Gender Differences in Patients with Gastric Cancer: A Systematic Review
Nerea Escandell Marí, Marta Sánchez-Ric, Marina Velez, Sabela Carballal, Leticia Moreira
Journal of Clinical Medicine.2026; 15(12): 4788. CrossRef

4,454 View
152 Download
5 Web of Science
3 Crossref

Gynecologic cancer

Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study: Young Wook Jeong, Dongkyu Eugene Kim, Ji Hyun Kim, Se Ik Kim, Hyeong In Ha, Sang-Yoon Park, Myong Cheol Lim; Cancer Res Treat. 2025;57(3):865-872. Published online November 4, 2024; DOI: https://doi.org/10.4143/crt.2024.899

Abstract PDF Supplementary Material PubReader ePub

Purpose
Nausea and vomiting are major non-hematological adverse events associated with niraparib maintenance therapy. This study aimed to investigate the time-trend patterns of niraparib-induced nausea and vomiting (NINV) and the associated risk factors in patients with ovarian cancer.
Materials and Methods
In this prospective study, we enrolled patients with stage III-IV epithelial ovarian cancer who received niraparib as frontline maintenance therapy. The clinicopathological characteristics and time-trend patterns of patients with NINV were collected through in-person surveys and electronic medical records from the National Cancer Center.
Results
Of 53 patients, 50 (94.3%) were diagnosed with high-grade serous ovarian carcinoma. BRCA mutations and homologous recombination deficiency (HRD) were identifi ed in 23 (43.4%) and 32 (60.4%) patients, respectively. Thirty-one patients (58.5%) had NINV. Time-trend analyses revealed that the fi rst peak intensity of NINV was reached at 3 h post-dose, and the second peak intensity was reached at 11 hour post-dose. NINV signifi cantly decreased from week 1 to weeks 8 and 12. In multivariate analyses of risk factors for NINV, HRD-positive tumors (p < 0.001) and prior experience of chemotherapy-induced nausea and vomiting (p=0.004) were associated with the occurrence of NINV.
Conclusion
Pre-emptive treatment with antiemetics is required to manage early-phase NINV during niraparib maintenance therapy in patients with risk factors. Additional larger studies are needed to confi rm these fi ndings and to develop optimal preventive strategies for NINV.

Citations

Citations to this article as recorded by

Niraparib

Reactions Weekly.2025; 2076(1): 354. CrossRef

5,865 View
255 Download
1 Crossref

Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study: Young-Il Kim, So Young Kim, Ji Hyun Kim, Jun Ho Lee, Young-Woo Kim, Keun Won Ryu, Jong-Hyock Park, Il Ju Choi; Cancer Res Treat. 2016;48(2):798-805. Published online July 14, 2015; DOI: https://doi.org/10.4143/crt.2015.117

Abstract PDF PubReader ePub

Purpose
The aim of this study was to investigate whether aspirin use can reduce the incidence of gastric cancer in patients with hypertension or type 2 diabetes. Materials and Methods A total of 200,000 patients with hypertension or type 2 diabetes were randomly selected from the Korean National Health Insurance claim database. Of these, 3,907 patients who used 100 mg of aspirin regularly (regular aspirin users) and 7,808 patients who did not use aspirin regularly (aspirin non-users) were selected at a frequency of 1:2, matched by age, sex, comorbid illnesses (type 2 diabetes and hypertension), and observation periods. The incidence of gastric cancer in this cohort was then assessed during the observation period of 2004 to 2010.
Results
In the matched cohort, the incidence rates of gastric cancer were 0.8% (31/3,907) for regular aspirin users and 1.1% (86/7,808) for aspirin non-users, but the cumulative incidence rates were not significantly different between groups (p=0.116, log-rank test). However, in multivariate analysis, regular aspirin users had a reduced risk of gastric cancer (adjusted hazard ratio [aHR], 0.71; 95% confidential interval [CI], 0.47 to 1.08; p=0.107). Duration of aspirin use showed significant association with reduction of gastric cancer risk (aHR for each year of aspirin use, 0.85; 95% CI, 0.73 to 0.99; p=0.044), particularly in patients who used aspirin for more than 3 years (aHR, 0.40; 95% CI, 0.16 to 0.98; p=0.045). Conclusion Long-term low-dose aspirin use was associated with reduced gastric cancer risk in patients with hypertension or type 2 diabetes.

Citations

Citations to this article as recorded by

Dose-response relationship between aspirin and gastric cancer risk: A systematic review and meta-analysis
Shan Zhang, Hongwei Wang, Jingjing Ji, Ruiyu Chai, Shiyi Song, Jikang Shi, Siyu Liu
Cancer Epidemiology.2025; 97: 102873. CrossRef
Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses
Xiao Bai, Si-Qi Ding, Xue-Ping Zhang, Ming-Hao Han, Dong-Qiu Dai
Cancers.2023; 15(2): 372. CrossRef
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells
Monica Susan, Ioana Macasoi, Iulia Pinzaru, Cristina Dehelean, Iosif Ilia, Razvan Susan, Ioana Ionita
Current Oncology.2023; 30(7): 6197. CrossRef
Prediction algorithm for gastric cancer in a general population: A validation study
Martin C. S. Wong, Eman Yee‐man Leung, Sarah T. Y. Yau, Sze Chai Chan, Shaohua Xie, Wanghong Xu, Junjie Huang
Cancer Medicine.2023; 12(21): 20544. CrossRef
Evaluation of clopidogrel use on gastric precancerous lesions: Does it have chemopreventive effect?
Taner AKYOL
Journal of Medicine and Palliative Care.2023; 4(5): 524. CrossRef
Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study
Jessica J P Shami, Jiaxi Zhao, Swathi Pathadka, Eric Yuk Fai Wan, Joseph Edgar Blais, Pareen Vora, Montse Soriano-Gabarró, Ka Shing Cheung, W K Leung, Ian C K Wong, Esther W Chan
BMJ Open.2022; 12(2): e050510. CrossRef
Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study
Sohee Kwon, Wenjie Ma, David A. Drew, Samuel J. Klempner, Brianna M. Leonardo, Jacqueline J. Flynn, Yin Cao, Edward L. Giovannucci, Ying Bao, Charles S. Fuchs, Mingyang Song, Andrew T. Chan
Cancer Prevention Research.2022; 15(4): 265. CrossRef
Association of Aspirin, Metformin, and Statin Use with Gastric Cancer Incidence and Mortality: A Nationwide Cohort Study
Mi Hee Cho, Tae Gon Yoo, Su-Min Jeong, Dong Wook Shin
Cancer Prevention Research.2021; 14(1): 95. CrossRef
Antibreast Cancer Activity of Aspirin-Conjugated Chalcone Polymeric Micelles
Do Young Lee, Kang Pa Lee, Suji Beak, Ji Su Park, Young Jin Kim, Kil-Nam Kim, Song-Rae Kim, Myeong Sik Yoon
Macromolecular Research.2021; 29(1): 105. CrossRef
Effect of frequently prescribed drugs on gastric cancer risk
Theresa Weltermann, Christian Schulz, Lukas Macke
Best Practice & Research Clinical Gastroenterology.2021; : 101741. CrossRef
Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials
Lijuan Wang, Rongqi Zhang, Lili Yu, Jiarui Xiao, Xuan Zhou, Xinxuan Li, Peige Song, Xue Li
Frontiers in Oncology.2021;[Epub] CrossRef
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
Chin-Hsiao Tseng
Biomolecules.2021; 11(7): 1022. CrossRef
Effect of aspirin use on gastric cancer incidence and survival: A systematic review and meta‐analysis
Ryota Niikura, Yoshihiro Hirata, Yoku Hayakawa, Takuya Kawahara, Atsuo Yamada, Kazuhiko Koike
JGH Open.2020; 4(2): 117. CrossRef
Positive association between dietary inflammatory index and gastric cancer risk: A systematic review and meta-analysis
Ying Liang, Haoyan Jiao, Lingbo Qu, Hao Liu
Nutrition and Cancer.2020; 72(8): 1290. CrossRef
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea
Minji Jung, Sukhyang Lee
Drugs & Aging.2020; 37(1): 43. CrossRef
Safety of Proton Pump Inhibitors Questioned Based on a Large Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Johanna Simin, Qing Liu, Romina Fornes, Nele Brusselaers
Gastroenterology.2020; 158(4): 1172. CrossRef
De novo malignancy risk in patients undergoing the first percutaneous coronary intervention: A nationwide population-based cohort study
Soongu Kwak, You-Jung Choi, Soonil Kwon, Seo-Young Lee, Seokhun Yang, Inki Moon, Hyun-Jung Lee, Heesun Lee, Jun-Bean Park, Kyungdo Han, Yong-Jin Kim, Hyung-Kwan Kim
International Journal of Cardiology.2020; 313: 25. CrossRef
Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
Peipei Liu, Úna C. McMenamin, Brian T. Johnston, Peter Murchie, Lisa Iversen, Amanda J. Lee, Pauline A. J. Vissers, Chris R. Cardwell
British Journal of Cancer.2020; 123(2): 307. CrossRef
Low‐dose aspirin and risk of gastric and oesophageal cancer: A population‐based study in the United Kingdom using The Health Improvement Network
Luis A. García Rodríguez, Montse Soriano‐Gabarró, Pareen Vora, Lucía Cea Soriano
International Journal of Cancer.2020; 147(9): 2394. CrossRef
Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin
Jiro Watari, Toshihiko Tomita, Katsuyuki Tozawa, Tadayuki Oshima, Hirokazu Fukui, Hiroto Miwa
Gut and Liver.2020; 14(3): 281. CrossRef
Acetylsalicylic Acid Exerts Potent Antitumor and Antiangiogenic Effects in Cutaneous and Uveal Melanoma Cell Lines
Dominique Fausto de Souza, Thupten Tsering, Miguel N. Burnier , Vasco Bravo-Filho, Ana Beatriz Toledo Dias, Mohamed Abdouh, Alicia Goyeneche, Julia Valdemarin Burnier
Ocular Oncology and Pathology.2020; 6(6): 442. CrossRef
Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Yan Qiao, Tingting Yang, Yong Gan, Wenzhen Li, Chao Wang, Yanhong Gong, Zuxun Lu
BMC Cancer.2018;[Epub] CrossRef
Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer
Min-hyung Kim, Jooyoung Chang, Warrick Junsuk Kim, Samprit Banerjee, Sang Min Park
American Journal of Gastroenterology.2018; 113(6): 845. CrossRef
Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis
Yu-Shan Lin, Chih-Ching Yeh, Shiang-Fu Huang, Yi-Sheng Chou, Li-Tang Kuo, Fung-Chang Sung, Chih-Hsin Muo, Chien-Tien Su, Fu-Hsiung Su, Mohammad R. Akbari
PLOS ONE.2018; 13(8): e0199014. CrossRef
Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer
Min-hyung Kim, Jooyoung Chang, Warrick Junsuk Kim, Samprit Banerjee, Sang Min Park
American Journal of Gastroenterology.2018; 113(6): 845. CrossRef
Chemoprevention of Gastric Cancer: Non-steroidal Anti-inflammatory Drugs Including Aspirin
Kee Don Choi
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(4): 169. CrossRef
Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer
Yuki Michigami, Jiro Watari, Chiyomi Ito, Ken Hara, Takahisa Yamasaki, Takashi Kondo, Tomoaki Kono, Katsuyuki Tozawa, Toshihiko Tomita, Tadayuki Oshima, Hirokazu Fukui, Takeshi Morimoto, Kiron M. Das, Hiroto Miwa
Scientific Reports.2017;[Epub] CrossRef
Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT
Jiang-Hua Ding, Li-Ya Yuan, Guo-An Chen
Oncology Letters.2017; 13(2): 647. CrossRef
Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis
Xuan-zhang Huang, You Chen, Jian Wu, Xi Zhang, Cong-cong Wu, Chao-ying Zhang, Shuang-shuang Sun, Wen-jun Chen
Oncotarget.2017; 8(3): 4781. CrossRef
Prognostic value of a novel FPR biomarker in patients with surgical stage II and III gastric cancer
Jing Zhang, Shu-Qi Li, Zhi-Hua Liao, Yu-Huan Jiang, Qing-Gen Chen, Bo Huang, Jing Liu, Yan-Mei Xu, Jin Lin, Hou-Qun Ying, Xiao-Zhong Wang
Oncotarget.2017; 8(43): 75195. CrossRef
Dietary inflammatory index and the risk of gastric cancer in a Korean population
Sunghee Lee, Jeonghee Lee, Il Ju Choi, Young-Woo Kim, Keun Won Ryu, Young-Il Kim, Jin-Kyoung Oh, Binh Thang Tran, Jeongseon Kim
Oncotarget.2017; 8(49): 85452. CrossRef

15,641 View
185 Download
36 Web of Science
31 Crossref

Patient’s Factors at Entering Hospice Affecting Length of Survival in a Hospice Center: Guk Jin Lee, Hye Shin Ahn, Se Eun Go, Ji Hyun Kim, Min Wu Seo, Seung Hun Kang, Yeo Ree Yang, Mi Yeong Lee, Ku Ock Lee, Sang Hoon Chun, Jong Youl Jin; Cancer Res Treat. 2015;47(1):1-8. Published online August 28, 2014; DOI: https://doi.org/10.4143/crt.2013.148

Abstract PDF PubReader ePub

Purpose
In order to provide effective hospice care, adequate length of survival (LOS) in hospice is necessary. However the reported average LOS is much shorter. Analysis of LOS in hospice has not been reported from Korea. We evaluated the duration of LOS and the factors associated with LOS at our hospice center.
Materials and Methods
We retrospectively examined 446 patients who were admitted to our hospice unit between January 2010 and December 2012. We performed univariate and multivariate analysis for analysis of factors associated with LOS.
Results
The median LOS was 9.5 days (range, 1 to 186 days). The LOS of 389 patients (86.8%) was< 1 month. At the time of admission to hospice, 112 patients (25.2%) were completely bedridden, 110 patients (24.8%) had mouth care only without intake, and 134 patients (30.1%) had decreased consciousness, from confusion to coma. The median time interval between the day of the last anticancer treatment and the day of hospice admission was 75 days. By analysis of the results of multivariate analysis, decreased intake and laboratory results showing increased total white blood cell (WBC), decreased platelet count, increased serum creatinine, increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) level were poor prognostic factors for survival in hospice.
Conclusion
Before hospice admission, careful evaluation of the patient’s performance, particularly the oral intake, and total WBC, platelet, creatinine, AST, ALT, and LDH level is essential, because these were strong predictors of shorter LOS. In the future, conduct of prospective controlled studies is warranted in order to confirm the relationship between potential prognostic factors and LOS in hospice.

Citations

Citations to this article as recorded by

Weight Loss Goals and Lifestyle Characteristics of Mongolian Participants in Korean Medicine-Based Weight Management Consultation: An Exploratory Cross-Sectional Survey
Minwoo Bang, Suyong Shin, Jungsang Kim, Minwhee Kang, Donghun Lee, Junho Kim, Chunghee Kim, Jiyoung Son, Seonghyeon Jeon, Byungsoo Kang
Journal of Korean Medicine.2026; 47(2): 203. CrossRef
Latent transition analysis of end-of-life care trajectories among cancer patients in South Korea: a nationwide cohort study
Goun Park, Wankyo Chung
BMC Health Services Research.2026;[Epub] CrossRef
Timing of hospice care initiation and aggressive care utilization in patients with cancer: a retrospective nationwide study in Korea
Boram Kim, Woorim Kim, Dae Hun Ryu, Jin Young Choi
Frontiers in Public Health.2026;[Epub] CrossRef
Changes in the palliative performance scale may be as important as the initial palliative performance scale for predicting survival in terminal cancer patients
Guk Jin Lee, Ji Hyun Gwak, Myoung Sim Kim, Mi Yeong Lee, Seo Ree Kim, Sang Hoon Chun, Jong Youl Jin
Palliative and Supportive Care.2021; 19(5): 547. CrossRef
Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study
Eun Ju Park, Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, Ki Sun Jung, So Yeon Oh, Yun Jeong Hong, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon
Cancer Research and Treatment.2021; 53(3): 881. CrossRef
Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study
Min-Seok Seo, In Cheol Hwang, Jaehun Jung, Hwanhee Lee, Jae Hee Choi, Jae-Yong Shim
BMC Palliative Care.2020;[Epub] CrossRef
The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Aleksandar Čubranić
Journal of Pain and Symptom Management.2018; 55(1): 22. CrossRef
Cancer-related hypercalcemia in oral cancer
T.-C. Lin, K.-L. Liang, L.-C. Lee, C.-Y. Hsu, T.-T. Yen
International Journal of Oral and Maxillofacial Surgery.2018; 47(6): 685. CrossRef
Physical Exercise: An Evaluation of a New Clinical Biomarker of Survival in Hospice Patients
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Lidija Gović-Golčić, Aleksandar Čubranić
American Journal of Hospice and Palliative Medicine®.2018; 35(11): 1377. CrossRef
Effects of a new medical insurance payment system for hospice patients in palliative care programs in Korea
Youngin Lee, Seung Hun Lee, Yun Jin Kim, Sang Yeoup Lee, Jeong Gyu Lee, Dong Wook Jeong, Yu Hyeon Yi, Young Jin Tak, Hye Rim Hwang, Mieun Gwon
BMC Palliative Care.2018;[Epub] CrossRef
Prediction of Patient Discharge Status Based on Indicators on Admission
Sung-In Chung, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Kyung-Mi Kim
The Korean Journal of Hospice and Palliative Care.2018; 21(3): 75. CrossRef
Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival
Christian Lunetta, Andrea Lizio, Mario Giovanni Melazzini, Eleonora Maestri, Valeria A. Sansone
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(1-2): 93. CrossRef
Safety, efficacy, and patient-perceived satisfaction of peripherally inserted central catheters in terminally ill cancer patients: a prospective multicenter observational study
Kwonoh Park, Hyun Jung Jun, So Yeon Oh
Supportive Care in Cancer.2016; 24(12): 4987. CrossRef

15,590 View
83 Download
11 Web of Science
13 Crossref

Case Report

A Case of Paraneoplastic Membranous Nephropathy Associated with Adenocarcinoma of the Lung: Ji Hyun Kim, Hyung Won Yang, Sung Hee Kwon, In Sook Woo, Young Iee Park, Myung Jae Park, No Won Jun, Jung Woo Noh, Jung Won Sim, Hye Kyung Ahn, Hyun Soon Lee; J Korean Cancer Assoc. 1998;30(4):737-742.

Abstract PDF: The paraneoplastic nephrotic syndrome can be diagnosed by clinical and immunologic features. We have had a case of paraneoplastic nephrotic syndrome in the patients with aadeno-carcinoma of the lung, whose diagnosis was made by excluding other causes of nephrotic syndrome. The type of renal lesion was membranous glomerulopathy which commonly occurs in carcinoma. The quantity of proteinuria in this patient had decreased according to the improvement of lung cancer with combination chemotherapy. After fourth chemotherapy he was refractory to treatment, and unfortunately he had passed away with cardiac tamponade.

4,647 View
22 Download

Original Articles

Germline Mutation of BRCA2 Gene in Korean Breast / Ovarian Cancer Families: Yong Jin Won, Jae Hwan Oh, Ji Hyun Kim, Dong Young Noh, Kuk Jin Choe, Soon Beom Kang, Lee Su Kim, Man Su Ro, Nam Sun Paik, Dae Hyun Yang, Se Min Oh, Soon Nam Lee, Kyung Kook Kim, Jae Gahb Park; J Korean Cancer Assoc. 1998;30(2):242-252.

Abstract PDF: PURPOSE
Recent discovery of BRCA1 and BRCA2 genes has made it possible to perform presymptomatic diagnosis in hereditary breast/ovarian cancer families. We have previously reported germline mutations of the BRCA1 gene in Korean hereditary breast/ovarian cancer families. In that study two out of 13 families were found to have germline mutations in BRCA1 gene. One was a nonsense mutation in codon 1815, and the other was a frameshift mutation due to 2 base-pair deletion in codon 1701 of BRCA1 gene. This study was intended to identify germline mutations of the BRCA2 gene in Korean breast/ovarian cancer families.
MATERIALS AND METHODS
Peripheral blood DNA was obtained from 10 breast cancer patients registered at the Korean Hereditary Tumor Registry with positive family history of breast and/or ovarian cancer. Exons 11 and 27 of the BRCA2 gene(together accounting for 50% of the coding region of the BRCA2 gene) were amplified by polymerase chain reaction(PCR) and screened for mutations by in vitro transcription/translation method. For confirmation of the mutations, automatic sequencing of the PCR products displaying abnormal truncated protein bands was perfomed.
RESULT
We identified an abnormal truncated protein in the exon 11 of the BRCA2 gene from a member of hereditary breast cancer family, SNU-B4. Sequencing analysis revealed a 4 bp deletion in codons 1248-49 of the exon 11, resulting in frameshift that led to premature stop codon and truncation of the protein product.
CONCLUSION
We have identified a germline mutation from a Korean hereditary breast cancer family. So far only one case of the same mutation has been registered in Database of BRCA2 mutation (BIC) by a commercial genetic diagnosis company, Myriad Genetics, Inc. Identification of the germline mutation in BRCA2 gene should aid in the accurate presymptomatic diagnosis of the at-risk members in this family.

4,300 View
34 Download

Studies on Constituents of the Higher Fungi of Korea ( LI ) Antitumor Components Extracted from the Cultured Mycelia of Volvariella bombycina: Ji Hyun Kim, Ha Won Kim, Jung Woo Kim, Eung Chil Choi, Byong Kak Kim; J Korean Cancer Assoc. 1985;17(2):205-217.

PDF

2,919 View
25 Download

Prognostic Factor Analysis of Aggressive Non - Hodgkin's Lymphoma Based on International Prognostic Index Model: Min Hee Ryu, Young Iee Park, Hark Kyun Kim, Dae Ho Lee, Joo Young Jeong, Dong Wan Kim, Im Il Na, Ji Hyun Kim, Se Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seon Yang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(6):1269-1278.

Abstract PDF: PURPOSE
International Prognostic Index Model (IPIM) in aggressive non-Hodgkin's lymphoma was published and accepted generally as a better predictive model for prognosis. This study was undertaken to identify prognostic factors of aggressive non- Hodgkin's lymphoma and usefulness of IPIM in Korea.
MATERIALS AND METHODS
Previously untreated, pathologically proven 226 aggressive non-Hodgkin's lymphoma patients who were treated with CHOP or COP-BLAM V between 1986 and 1995 in Seoul National University Hospital were evaluated for clinical features predictive of overall survival.
RESULTS
Complete response (CR) was reached in 76% of all patients. With a median follow-up of 62 months, 5-year disease free survival of complete reponders was 67% and 5-year overall survival of all patients was 54%. In a univriate analysis, age, ECOG performance status, Ann Arbor stage, histologic subtype, bone marrow involvement, bulkiness, serum LDH level and number of extranodal involvement were significant prognostic factors for CR and survival (p<0.05). Of these, by multivariate analysis, age(RR 0.4, 95% CI 0.2~0.9) alone was a independent prognostic factor for CR. For disease free survival, no independent prognostic factor was found. For overall survival, Ann Arbor stage (RR 1.7, 95% CI 1.1~2.8), age (RR 1.7, 95% CI 1.1~2.6), Histologic subtype (RR 1.7, 95% CI 1.1~2.8), serum LDH level (RR 1.7, 95% CI 1.1~2.6) and bone marrow involvement (RR 1.8, 95% CI 1.0~3.1) were independent prognostic factors. According to risk group of IPIM, 5-year overall survival rate was 72% in low risk group, 46% in low intermediate risk group, 32% in high intermediate risk group, respectively, and median survival of high risk group was 12 months (RR 1, 2.3, 4.3, 6.4 respectively).
CONCLUSION
IPIM is a useful model for identifying poor prognostic groups in aggressive non-Hodgkin's lymphoma.

3,958 View
17 Download

First
Prev
Page of 1
Next
Last

Search